- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04854044
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Phase 1b Study of ONC201 and Radiotherapy in Preoperative Recurrent Glioblastoma (GBM) Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the safety and tolerability of Akt/ERK Inhibitor ONC201 (ONC201) in combination with radiotherapy before a tumor resection in recurrent glioblastoma (GBM) patients.
II. To determine the ability of ONC201 to decrease glioblastoma-initiating cells as determined by percentage of neurosphere formation of treated brain tumor tissues compared to non-treated brain tumor tissues.
SECONDARY OBJECTIVES:
I. To determine the ability of ONC201 to decrease glioblastoma-initiating cells as determined by expression of glioma stem cells using ribonucleic acid-sequencing (RNA-Seq) of treated brain tumor tissues compared to non-treated brain tumor tissues.
II. To assess the ability of ONC201 to inhibit Akt by evaluating progressive disease (PD) markers by immunohistochemistry such as Sox2, Oct3/4, Nanog, Akt and p-Akt, GSK3 and pGSK3alpha.
EXPLORATORY OBJECTIVES:
I. To estimate progression-free survival (PFS) and overall survival (OS). II. To determine the immunogenicity of the combination of ONC201 + radiation therapy (RT) via immune cell studies.
III. To determine if the combination of ONC201 + RT leads to increase cholesterol synthesis.
IV. To determine molecular markers of response to ONC201 in correlation to survival such as DRD5 expression.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo radiation therapy for 10 fractions over 2 weeks, and receive ONC201 orally (PO) daily on days 1, 2, 8, and 9. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. Beginning 7 days from last pre-surgery dose of ONC201, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
ARM II: Patients undergo radiation therapy for 10 fractions over 2 weeks. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. After recovery from surgery, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 3 months.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must have histologically proven glioblastoma or gliosarcoma which is progressive or recurrent following radiation therapy +/- chemotherapy
- Participants must have evaluable, supratentorial contrast-enhancing progressive or recurrent glioblastoma or gliosarcoma by magnetic resonance imaging (MRI) imaging within 14 days of study treatment initiation. Participants must be able to tolerate MRIs
- Participants can have any number of prior relapses
Participants must have recovered from severe toxicity of prior therapy. The following intervals from previous treatments are required to be eligible:
- 12 weeks from the completion of radiation
- 6 weeks from a nitrosourea chemotherapy or mitomycin C
- 23 days from temozolomide chemotherapy
- 4-weeks from other cytotoxic therapy unless noted above
- 4 weeks or 5-half-lives (whichever is shorter) from any other investigational (not Food and Drug Administration [FDA]-approved) agents (including vaccines)
- Participants must be undergoing surgery that is clinically indicated as determined by their care providers. Patients must be eligible for surgical resection with the expectation that the surgeon is able to resect at least 300 mg of tumor with low risk of inducing neurological injury
- Participants must be undergoing radiotherapy that is clinically indicated as determined by their care providers. The field of radiation must overlap the area of tumor planned for surgical resection. Participants must have a minimum tumor size of 2 x 2 cm^2 based on MRI scan prior to surgery
- Participants must be 18 years of age or older
- Participants must have a Karnofsky performance status >= 60% (i.e. the participant must be able to care for himself/herself with occasional help from others)
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 9 g/dL
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
- Creatinine =< institutional upper limit of normal OR creatinine clearance >= 50 mL/min/1.73m^2 for patients with creatinine levels above institutional normal
- Activated partial thromboplastin time/ partial thromboplastin time (APTT/PTT) =< 1.5 x institutional upper limit of normal (unless participant is receiving anticoagulant therapy as long as prothrombin time [PT] or aPTT is within therapeutic range of intended use of anticoagulants)
- Female participants of childbearing potential must have a negative urine or serum pregnancy test prior to study entry. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum follicle stimulating hormone [FSH] levels > 40 mIU/mL and estradiol < 20 pg/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
- Female participants of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug. Women who are nursing should discontinue nursing prior to starting study drug
- Participants must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder. Patients with prior malignancies must be disease-free for >= three years
- Participants must be able to swallow whole capsules
- Participants must have at least 20 (preferably 40) slides of archival tumor tissue from a prior surgery demonstrating GBM
- Participants must have the ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Participants receiving any other investigational agents or using an investigational device are ineligible
- Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 are ineligible
- Participants may not have had prior treatment with ONC201
- Participants may have had prior treatment with bevacizumab/VEGFR inhibitors, but last dose of treatment must be at least 4 weeks prior to the date of planned tumor resection
- Participants may not be on concurrent treatment with Optune device. Prior use of the device is allowable
- Participants must not have evidence of significant hematologic, renal, or hepatic dysfunction
Participants with a history of any of the following within the last 6 months prior to study entry are ineligible:
- Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures
- Ischemic cerebrovascular event, including transient ischemic attack (TIA) and artery revascularization procedures
- Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia)
- Placement of a pacemaker for control of rhythm
- New York Heart Association (NYHA) class III or IV heart failure
- Participants with known significant active cardiovascular or pulmonary disease at the time of study entry are ineligible
- Participants receiving therapeutic agents known to prolong QT interval will be excluded. Patients on sertraline which has the conditional risk of prolonging the QT interval will be allowed on study if they hold sertraline on the day of ONC201 administration
- Participants using concomitant CYP3A4/5 inhibitors within 72 hours prior to starting study drug administration are ineligible
- Participants with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible
- Pregnant women are excluded from this study because there is unknown risk of ONC201 on the fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother on ONC201, breastfeeding should be discontinued if the mother is treated with ONC201
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (ONC201, radiation therapy, resection)
Patients undergo radiation therapy for 10 fractions over 2 weeks, and receive ONC201 PO daily on days 1, 2, 8, and 9. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection.
Beginning 7 days from last pre-surgery dose of ONC201, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
|
Undergo radiation therapy
Other Names:
Undergo surgical resection
Other Names:
Given orally
Other Names:
|
Experimental: Arm II (ONC201, radiation therapy, resection)
Patients undergo radiation therapy for 10 fractions over 2 weeks.
Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection.
After recovery from surgery, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
|
Undergo radiation therapy
Other Names:
Undergo surgical resection
Other Names:
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 90 days after the last study treatment
|
Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
|
Up to 90 days after the last study treatment
|
Percentage of neurosphere formation
Time Frame: At the tumor resection during surgery
|
A two-sample two-sided t-test will be performed to compare the percentage of neurosphere formation of treated brain tumor tissues and non-treated brain tumor tissues.
|
At the tumor resection during surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expression of glioma stem cells using ribonucleic acid-sequencing (RNA-Seq)
Time Frame: At the tumor resection during surgery
|
Will be compared between treated brain tumor tissues and non-treated brian tumor tissues.
Markers for expression of glioma stem cells as determined by RNA-Seq and makers indicating cellular pathways leading to formation of GICs, such as Sox2, Oct3/4, Nanog, Akt and p-Akt, GSK3 and pGSK3alpha, will be examined graphically and summarized by descriptive statistics.
Changes in markers pre- and post- treatment will be assessed using paired t-tests or Wilcoxon signed rank test.
Between-group differences in these markers will be assessed by two-sample t-test or Wilcoxon rank-sum test for quantitative variables and by Chi-squared test or Fisher's exact test for categorical ones.
|
At the tumor resection during surgery
|
Pharmacodynamic (PD) markers
Time Frame: At the tumor resection during surgery
|
Evaluated by immunohistochemistry such as Sox2, Oct3/4, Nanog, Akt and p-Akt, GSK3 and pGSK3alpha.
Markers for expression of glioma stem cells as determined by RNA-Seq and makers indicating cellular pathways leading to formation of GICs, such as Sox2, Oct3/4, Nanog, Akt and p-Akt, GSK3 and pGSK3alpha, will be examined graphically and summarized by descriptive statistics.
Changes in markers pre- and post- treatment will be assessed using paired t-tests or Wilcoxon signed rank test.
Between-group differences in these markers will be assessed by two-sample t-test or Wilcoxon rank-sum test for quantitative variables and by Chi-squared test or Fisher's exact test for categorical ones.
|
At the tumor resection during surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Up to 4 years
|
Kaplan-Meier (KM) curves and the median time to progression estimated from the KM curves will be provided for each group as appropriate.
Log-rank test will be used to compare Group A versus Group B.
|
Up to 4 years
|
Overall survival
Time Frame: Up to 4 years
|
KM curves and the median time to progression estimated from the KM curves will be provided for each group as appropriate.
Log-rank test will be used to compare Group A versus Group B.
|
Up to 4 years
|
Pharmacodynamic markers
Time Frame: At the tumor resection during surgery
|
Post-treatment tissues will be assessed for Pharmacodynamic markers (Sox2, Oct3/4, Nanog, Akt and p-Akt, GSK3 and pGSK3alpha) by RNA-seq and IHC to evaluate the immunogenicity of ONC201 for recurrent glioblastoma.
|
At the tumor resection during surgery
|
Determine if the combination of ONC201 + RT leads to increase cholesterol synthesis
Time Frame: At screening, pre-surgery, every 4 weeks post-surgery, and the end of study treatment, up to 48 months
|
Cholesterol synthesis level will be evaluated via laboratory testing of RNA-seq.
|
At screening, pre-surgery, every 4 weeks post-surgery, and the end of study treatment, up to 48 months
|
Determine molecular markers of response to ONC201 in correlation to survival such as DRD5 expression
Time Frame: Up to 4 years
|
Pre-treatment archival tumor tissue and post-treatment tumor tissue will be obtained to evaluate other molecular markers of response to ONC201 + RT, including pharmacodynamic markers such as DRD2 and DRD5.
|
Up to 4 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Phioanh Nghiemphu, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Recurrence
- Gliosarcoma
- Antineoplastic Agents
- TIC10 compound
Other Study ID Numbers
- 21-000054 (Other Identifier: UCLA / Jonsson Comprehensive Cancer Center)
- NCI-2021-02121 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P50CA211015 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; Northwest Biotherapeutics; Brain Tumor Funders CollaborativeWithdrawnGliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Small Cell Glioblastoma | Giant Cell GlioblastomaUnited States
Clinical Trials on Radiation Therapy
-
NRG OncologyNational Cancer Institute (NCI)RecruitingUnrectable or Locally Recurrent Hepatocellular CarcinomaUnited States
-
Medical College of WisconsinRecruitingHead and Neck CancerUnited States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of California, San FranciscoVarian Medical SystemsRecruitingStage IV Anal Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Postneoadjuvant Therapy Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumor | Central Nervous System TumorUnited States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
-
Medical College of WisconsinActive, not recruitingHigh-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB) (SIB)Prostate CancerUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina
-
NYU Langone HealthCompletedBreast CancerUnited States